<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2840">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04323592</url>
  </required_header>
  <id_info>
    <org_study_id>MP-19 023_2020</org_study_id>
    <nct_id>NCT04323592</nct_id>
  </id_info>
  <brief_title>Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome</brief_title>
  <acronym>MP-C19</acronym>
  <official_title>Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Trieste</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Trieste</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 infection is overwhelming Italian healthcare. There is an urgent need for a solution
      to the lack of ICU beds and increasing deaths day after day.

      A recent retrospective Chinese paper (JAMA Intern Med, online March 13, 2020) showed
      impressive positive effect of methylprednisolone (MP) on survival of SARS-CoV-2 critically
      ill patients. Moreover, the Italian Infectious Disease leading institution guidelines for
      COVID-19 clinical management included as an option for patients with &quot;incipient worsening of
      respiratory functions&quot; methylprednisolone treatment at an approximate dose of 80mg.

      The main objective of this multi-centre observational trial is to analyse the association of
      low dose prolonged infusion of methylprednisolone (MP) for patients with severe acute
      respiratory syndrome with composite primary end-point (ICU referral, need for intubation,
      in-hospital death at day 28).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of two groups of patients SARS-CoV-2 positive with severe acute respiratory
      syndrome:

        1. Exposed to low prolonged doses of Methylprednisolone

        2. Not exposed to corticosteroids (standard of care alone)

      The two group will be weighted by means of a propensity score according to:

        1. Sex

        2. Age

        3. C-reactive protein (CRP) at baseline

        4. Sequential Organ Failure Assessment (SOFA) score at baseline

        5. PaO2/FiO2 ratio at baseline (ratio of arterial oxygen partial pressure to fractional
           inspired oxygen)

      Anti-viral agents, chloroquine, respiratory support (any), and antibiotics (any) are allowed
      in each study group. Corticosteroids use, other than per-protocol Methylprednisolone in the
      exposed group is a reason for dropout.

        1. The exposed group is treated with Methylprednisolone at study entry (baseline) according
           to a protocol based on the Italian national recommendations for COVID-19 management: a
           loading dose of 80 mg IV, followed by an infusion of 80 mg/day in 240 mL normal saline
           at 10 mL/h. The infusion is continued for at least eight days and until achieving either
           a PaO2:FiO2 &gt; 350 mmHg or a CRP &lt; 20 mg/L. Treatment is then switched to oral
           administration of Methylprednisolone 16 mg or 20 mg IV twice daily until CRP returns to
           &lt; 20% of normal range and/or PaO2:FiO2 &gt; 400 or SatHbO2 ≥ 95%. The decision to apply the
           protocol to Covid-19 is left to the discretion of the treating team for each individual
           patient.

        2. Unexposed patients will be selected from concurrent consecutive COVID-19 patients with
           the same inclusion and exclusion criteria and blinded to outcome data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2020</start_date>
  <completion_date type="Actual">May 10, 2020</completion_date>
  <primary_completion_date type="Actual">May 10, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>We reported below the number of participants meeting at least one of three among death or ICU admission or Invasive mechanical ventilation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In-hospital Death Within 28 Days</measure>
    <time_frame>28 days</time_frame>
    <description>We reported below the number of participants who died within 28 days, during the hospital stay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Admission to Intensive Care Unit (ICU)</measure>
    <time_frame>28 days</time_frame>
    <description>We reported below the number of participants admitted to ICU within 28 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endotracheal Intubation (Invasive Mechanical Ventilation)</measure>
    <time_frame>28 days</time_frame>
    <description>We reported below the number of participants who needed endotracheal intubation during ICU admission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive Protein (CRP)</measure>
    <time_frame>7 days</time_frame>
    <description>Change in C-reactive protein after 7 days from baseline. A reduction of CRP reveals a laboratory improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Free From Mechanical Ventilation</measure>
    <time_frame>28 days</time_frame>
    <description>number of days free from mechanical ventilation (both invasive and non-invasive) by day 28</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">173</enrollment>
  <condition>Severe Acute Respiratory Syndrome (SARS) Pneumonia</condition>
  <condition>Coronavirus Infections</condition>
  <condition>ARDS, Human</condition>
  <arm_group>
    <arm_group_label>Exposed to Methylprednisolone</arm_group_label>
    <description>Consecutive SARS-CoV-2 positive patients with severe acute respiratory syndrome treated with methylprednisolone (MP) at low prolonged dose, fulfilling inclusion and exclusion criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-exposed to Methylprednisolone</arm_group_label>
    <description>Concurrent patients fulfilling the same inclusion and exclusion criteria, never treated with steroids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Usual standard of care plus Methylprednisolone (MP) 80 mg/kg IV bolus, followed by MP infusion of 80 mg/day in 240 mL normal saline at 10 mL/h. The infusion is continued for at least eight days and until achieving either a PaO2:FiO2 &gt; 350 mmHg or a CRP &lt; 20 mg/L. Treatment is then switched to oral administration of Methylprednisolone 16 mg or 20 mg IV twice daily until CRP returns to &lt; 20% of normal range and/or PaO2:FiO2 &gt; 400 or SatHbO2 ≥ 95%. The decision to apply the protocol to Covid-19 is left to the discretion of the treating team for each individual patient.</description>
    <arm_group_label>Exposed to Methylprednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care</intervention_name>
    <description>usual standard of care:
oxygen therapy (regular or high-flow) and monitoring
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
ECMO when needed and available
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
    <arm_group_label>Exposed to Methylprednisolone</arm_group_label>
    <arm_group_label>Non-exposed to Methylprednisolone</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Previous specific informed consent, blood samples of some patients treated with
      methylprednisolone were collected, in order to have the possibility to do
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients admitted to Respiratory High dependency units for severe acute
        respiratory syndrome associated to COVID-19
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. SARS-CoV-2 positive

          2. Age &gt;17 years and &lt; 80 years

          3. P/F &lt; 250 mmHg

          4. Bilateral pneumonia (infiltrates/interstitial)

          5. CRP &gt;10mg/dL (or &gt;100mg/L)

          6. Alternatively to 4-5-6 criteria a diagnosis of ARDS according to the Berlin definition
             (Ranieri M, et al. JAMA 2012)

        Exclusion Criteria:

          -  Heart failure as predominant cause of acute respiratory failure

          -  Decompensated liver cirrhosis

          -  Cancer

          -  Organ transplantation

          -  HIV+

          -  dialysis

          -  long-term oxygen therapy, home mechanical ventilation

          -  Idiopathic pulmonary fibrosis

          -  Progressive neuromuscular disorders (e.g. Duchenne, Pompe, ALS)

          -  Dementia or decompensated psychiatric diseases

          -  immunosuppressive treatments

          -  Chronic use of corticosteroids

          -  Use of Tocilizumab

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Confalonieri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Trieste</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marco Confalonieri</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <zip>34149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Nicastri E, Petrosillo N, Ascoli Bartoli T, Lepore L, Mondi A, Palmieri F, D'Offizi G, Marchioni L, Murachelli S, Ippolito G, Antinori A. National Institute for the Infectious Diseases &quot;L. Spallanzani&quot;, IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep. 2020 Mar 16;12(1):8543. doi: 10.4081/idr.2020.8543. eCollection 2020 Feb 25.</citation>
    <PMID>32218915</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <results_first_submitted>May 21, 2020</results_first_submitted>
  <results_first_submitted_qc>May 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2020</results_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Trieste</investigator_affiliation>
    <investigator_full_name>marco confalonieri</investigator_full_name>
    <investigator_title>Head of Pulmonology and Critical care Dept.</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2,</keyword>
  <keyword>SARS</keyword>
  <keyword>ARDS</keyword>
  <keyword>Methylprednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Anonymised data will be available only to data manager who can visualise clinical chart anytime when is needed</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/ICF_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/SAP_004.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/Prot_006.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exposed to Methylprednisolone</title>
          <description>SARS-CoV-2 positive patients with severe acute respiratory syndrome consecutively treated with methylprednisolone (MP) at prolonged dose.
Inclusion criteria checked, the patient undergo 80mg iv bolus of MP followed by infusion (10cc/h) of MP in 240cc 0.9% saline every day until PaO2/FiO2 increase over 350 and/or CRP decrease below 20mg/L, then MP is administered PO tapering slowly until normal CRP values (+20%) are reached.
Methylprednisolone: after initial 80mg iv bolus followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
        </group>
        <group group_id="P2">
          <title>Non-exposed to Methylprednisolone</title>
          <description>Concurrent patients with the same inclusion/section exclusion criteria never treated with steroids, strictly matched according to gender and age (+/-10 years) and other three parameters:
CRP, SOFA score, PaO2:FiO2 -&gt; each parameter must be &lt;20% difference between case and control.
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exposed to Methylprednisolone</title>
          <description>SARS-CoV-2 positive patients with severe acute respiratory syndrome consecutively treated with methylprednisolone (MP) at low prolonged dose.
At admission, inclusion criteria checked, the patient undergo 80mg iv bolus of MP followed by infusion (10cc/h) of MP in 240cc 0.9% saline every day until PaO2/FiO2 increase over 350 and/or CRP decrease below 20mg/L, then MP is administered PO tapering until normal CRP values (+20%) are reached.
Methylprednisolone: Methylprednisolone given at low prolonged dose infusion after initial 80mg iv bolus at admission followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description
standard care: usual standard of care:
oxygen therapy (regular or high-flow) and monitoring
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
ECMO when needed and available
pronati</description>
        </group>
        <group group_id="B2">
          <title>Non-exposed to Methylprednisolone</title>
          <description>Concurrent patients with the same inclusion/section exclusion criteria never treated with steroids, strictly matched according to gender and age (+/-10 years) and other three parameters:
CRP, SOFA score, PaO2:FiO2 -&gt; each parameter must be &lt;20% difference between case and control.
standard care: usual standard of care:
oxygen therapy (regular or high-flow) and monitoring
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
ECMO when needed and available
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="173"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.39" spread="10.73"/>
                    <measurement group_id="B2" value="67.08" spread="8.24"/>
                    <measurement group_id="B3" value="65.79" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Italy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-reactive Protein</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136.92" spread="72.57"/>
                    <measurement group_id="B2" value="148.64" spread="75.59"/>
                    <measurement group_id="B3" value="143.01" spread="74.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PaO2/FiO2</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152.02" spread="49.84"/>
                    <measurement group_id="B2" value="151.01" spread="60.26"/>
                    <measurement group_id="B3" value="151.50" spread="55.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sequential Organ Failure Assessment (SOFA) Score</title>
          <description>Sum of subscales scoring the function of: nervous system, kidneys, coagulation, respiratory system, cardiovascular system, liver.
Values ranging 0-24; higher values represent worse outcome.</description>
          <units>score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="B2" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="B3" value="3" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lactates</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.76" spread="1.97"/>
                    <measurement group_id="B2" value="1.34" spread="0.51"/>
                    <measurement group_id="B3" value="1.52" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lymphocytes</title>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="622.28" spread="650.62"/>
                    <measurement group_id="B2" value="954.5" spread="914.7"/>
                    <measurement group_id="B3" value="938.94" spread="797.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>D-dimer</title>
          <units>ug/L Fibrinogen Equivalent Units (FEU)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="780" lower_limit="530" upper_limit="1207"/>
                    <measurement group_id="B2" value="890" lower_limit="506.75" upper_limit="1757"/>
                    <measurement group_id="B3" value="813" lower_limit="518" upper_limit="1560.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>lactate dehydrogenase (LDH)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="380" spread="132.93"/>
                    <measurement group_id="B2" value="413.06" spread="143.83"/>
                    <measurement group_id="B3" value="396.41" spread="138.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Respiratory rate</title>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.74" spread="5.95"/>
                    <measurement group_id="B2" value="25.27" spread="6.76"/>
                    <measurement group_id="B3" value="24.55" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28</title>
        <description>We reported below the number of participants meeting at least one of three among death or ICU admission or Invasive mechanical ventilation.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exposed to Methylprednisolone</title>
            <description>SARS-CoV-2 positive patients with severe acute respiratory syndrome consecutively treated with methylprednisolone (MP) at prolonged dose.
Inclusion criteria checked, the patient undergo 80mg iv bolus of MP followed by infusion (10cc/h) of MP in 240cc 0.9% saline every day until PaO2/FiO2 increase over 350 and/or CRP decrease below 20mg/L, then MP is administered PO tapering slowly until normal CRP values (+20%) are reached.
Methylprednisolone: after initial 80mg iv bolus followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
          </group>
          <group group_id="O2">
            <title>Non-exposed to Methylprednisolone</title>
            <description>Concurrent patients with the same inclusion/section exclusion criteria never treated with steroids, strictly matched according to gender and age (+/-10 years) and other three parameters:
CRP, SOFA score, PaO2:FiO2 -&gt; each parameter must be &lt;20% difference between case and control.
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28</title>
          <description>We reported below the number of participants meeting at least one of three among death or ICU admission or Invasive mechanical ventilation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>In-hospital Death Within 28 Days</title>
        <description>We reported below the number of participants who died within 28 days, during the hospital stay.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exposed to Methylprednisolone</title>
            <description>SARS-CoV-2 positive patients with severe acute respiratory syndrome consecutively treated with methylprednisolone (MP) at prolonged dose.
Inclusion criteria checked, the patient undergo 80mg iv bolus of MP followed by infusion (10cc/h) of MP in 240cc 0.9% saline every day until PaO2/FiO2 increase over 350 and/or CRP decrease below 20mg/L, then MP is administered PO tapering slowly until normal CRP values (+20%) are reached.
Methylprednisolone: after initial 80mg iv bolus followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
          </group>
          <group group_id="O2">
            <title>Non-exposed to Methylprednisolone</title>
            <description>Concurrent patients with the same inclusion/section exclusion criteria never treated with steroids, strictly matched according to gender and age (+/-10 years) and other three parameters:
CRP, SOFA score, PaO2:FiO2 -&gt; each parameter must be &lt;20% difference between case and control.
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
          </group>
        </group_list>
        <measure>
          <title>In-hospital Death Within 28 Days</title>
          <description>We reported below the number of participants who died within 28 days, during the hospital stay.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Admission to Intensive Care Unit (ICU)</title>
        <description>We reported below the number of participants admitted to ICU within 28 days.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exposed to Methylprednisolone</title>
            <description>SARS-CoV-2 positive patients with severe acute respiratory syndrome consecutively treated with methylprednisolone (MP) at prolonged dose.
Inclusion criteria checked, the patient undergo 80mg iv bolus of MP followed by infusion (10cc/h) of MP in 240cc 0.9% saline every day until PaO2/FiO2 increase over 350 and/or CRP decrease below 20mg/L, then MP is administered PO tapering slowly until normal CRP values (+20%) are reached.
Methylprednisolone: after initial 80mg iv bolus followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
          </group>
          <group group_id="O2">
            <title>Non-exposed to Methylprednisolone</title>
            <description>Concurrent patients with the same inclusion/section exclusion criteria never treated with steroids, strictly matched according to gender and age (+/-10 years) and other three parameters:
CRP, SOFA score, PaO2:FiO2 -&gt; each parameter must be &lt;20% difference between case and control.
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
          </group>
        </group_list>
        <measure>
          <title>Admission to Intensive Care Unit (ICU)</title>
          <description>We reported below the number of participants admitted to ICU within 28 days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endotracheal Intubation (Invasive Mechanical Ventilation)</title>
        <description>We reported below the number of participants who needed endotracheal intubation during ICU admission</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exposed to Methylprednisolone</title>
            <description>SARS-CoV-2 positive patients with severe acute respiratory syndrome consecutively treated with methylprednisolone (MP) at prolonged dose.
Inclusion criteria checked, the patient undergo 80mg iv bolus of MP followed by infusion (10cc/h) of MP in 240cc 0.9% saline every day until PaO2/FiO2 increase over 350 and/or CRP decrease below 20mg/L, then MP is administered PO tapering slowly until normal CRP values (+20%) are reached.
Methylprednisolone: after initial 80mg iv bolus followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
          </group>
          <group group_id="O2">
            <title>Non-exposed to Methylprednisolone</title>
            <description>Concurrent patients with the same inclusion/section exclusion criteria never treated with steroids, strictly matched according to gender and age (+/-10 years) and other three parameters:
CRP, SOFA score, PaO2:FiO2 -&gt; each parameter must be &lt;20% difference between case and control.
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
          </group>
        </group_list>
        <measure>
          <title>Endotracheal Intubation (Invasive Mechanical Ventilation)</title>
          <description>We reported below the number of participants who needed endotracheal intubation during ICU admission</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-reactive Protein (CRP)</title>
        <description>Change in C-reactive protein after 7 days from baseline. A reduction of CRP reveals a laboratory improvement.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exposed to Methylprednisolone</title>
            <description>SARS-CoV-2 positive patients with severe acute respiratory syndrome consecutively treated with methylprednisolone (MP) at prolonged dose.
Inclusion criteria checked, the patient undergo 80mg iv bolus of MP followed by infusion (10cc/h) of MP in 240cc 0.9% saline every day until PaO2/FiO2 increase over 350 and/or CRP decrease below 20mg/L, then MP is administered PO tapering slowly until normal CRP values (+20%) are reached.
Methylprednisolone: after initial 80mg iv bolus followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
          </group>
          <group group_id="O2">
            <title>Non-exposed to Methylprednisolone</title>
            <description>Concurrent patients with the same inclusion/section exclusion criteria never treated with steroids, strictly matched according to gender and age (+/-10 years) and other three parameters:
CRP, SOFA score, PaO2:FiO2 -&gt; each parameter must be &lt;20% difference between case and control.
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-reactive Protein (CRP)</title>
          <description>Change in C-reactive protein after 7 days from baseline. A reduction of CRP reveals a laboratory improvement.</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-82.08" spread="28.24"/>
                    <measurement group_id="O2" value="-34.34" spread="66.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Free From Mechanical Ventilation</title>
        <description>number of days free from mechanical ventilation (both invasive and non-invasive) by day 28</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Exposed to Methylprednisolone</title>
            <description>SARS-CoV-2 positive patients with severe acute respiratory syndrome consecutively treated with methylprednisolone (MP) at prolonged dose.
Inclusion criteria checked, the patient undergo 80mg iv bolus of MP followed by infusion (10cc/h) of MP in 240cc 0.9% saline every day until PaO2/FiO2 increase over 350 and/or CRP decrease below 20mg/L, then MP is administered PO tapering slowly until normal CRP values (+20%) are reached.
Methylprednisolone: after initial 80mg iv bolus followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
          </group>
          <group group_id="O2">
            <title>Non-exposed to Methylprednisolone</title>
            <description>Concurrent patients with the same inclusion/section exclusion criteria never treated with steroids, strictly matched according to gender and age (+/-10 years) and other three parameters:
CRP, SOFA score, PaO2:FiO2 -&gt; each parameter must be &lt;20% difference between case and control.
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Free From Mechanical Ventilation</title>
          <description>number of days free from mechanical ventilation (both invasive and non-invasive) by day 28</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.11" spread="8.73"/>
                    <measurement group_id="O2" value="14.34" spread="11.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Exposed to Methylprednisolone</title>
          <description>SARS-CoV-2 positive patients with severe acute respiratory syndrome consecutively treated with methylprednisolone (MP) at prolonged dose.
Inclusion criteria checked, the patient undergo 80mg iv bolus of MP followed by infusion (10cc/h) of MP in 240cc 0.9% saline every day until PaO2/FiO2 increase over 350 and/or CRP decrease below 20mg/L, then MP is administered PO tapering slowly until normal CRP values (+20%) are reached.
Methylprednisolone: after initial 80mg iv bolus followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)
pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
        </group>
        <group group_id="E2">
          <title>Non-exposed to Methylprednisolone</title>
          <description>Concurrent patients with the same inclusion/section exclusion criteria never treated with steroids, strictly matched according to gender and age (+/-10 years) and other three parameters:
CRP, SOFA score, PaO2:FiO2 -&gt; each parameter must be &lt;20% difference between case and control.
standard care: usual standard of care:
respiratory support
empiric antibiotic therapy
mechanical ventilation (invasive or noninvasive)pronation when possible
other treatment which can be used are: antivirals, chloroquine, vitamins</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>QT elongation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bacterial superinfection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminase elevation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="83"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Marco Confalonieri</name_or_title>
      <organization>University of Trieste</organization>
      <phone>+393356895168 ext 4667</phone>
      <email>mconfalonieri@units.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

